Answers are grounded in this paper and cite their sources.
Phase 1 and 2 clinical trial data indicate that brentuximab vedotin is efficacious and safe in patients with relapsed and refractory CD30-positive lymphomas. This agent is being investigated in combination with chemotherapy to further elucidate its role in lymphoma therapy.
No takes yet. Share an insight, caveat, or question.
Stephanie S Minich (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: